Mantle cell lymphoma laboratory findings: Difference between revisions

Jump to navigation Jump to search
← Older edit
VisualWikitext
Ali Akram (talk | contribs)
528 edits
No edit summary
Ali Akram (talk | contribs)
528 edits
No edit summary
 
(9 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{ Mantle cell lymphoma }}
{{Mantle cell lymphoma }}


{{CMG}}; {{AE}} {{Akram}} {{AS}}
{{CMG}}; {{AE}} {{Akram}} {{AS}}
==Overview==
==Overview==
Laboratory tests for mantle cell lymphoma include [[complete blood count]] (CBC), blood chemistry studies, [[cytogenetic analysis]], [[flow cytometry]], [[immunohistochemistry]], [[genetic testing]], [[FISH]], [[PCR]], and [[immunophenotyping]].
Laboratory tests for mantle cell lymphoma include [[complete blood count]] (CBC), [[comprehensive metabolic panel]], [[LDH]] levels, [[Hepatitis B/Laboratory Tests|Hepatitis B]] testing if treatment with [[rituximab]] is planned, [[uric acid]] levels, [[beta-2-microglobulin]], pregnancy testing in woman of child-bearing age, [[flow cytometry]], [[immunohistochemistry]], [[genetic testing]] and [[FISH]].  
==Laboratory tests==
==Laboratory tests==
Laboratory tests for mantle cell lymphoma include:<ref name=”seer”>National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref>
Laboratory tests for mantle cell lymphoma include:<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref>
* [[Complete blood count]] (CBC) with differential count
* [[Complete blood count]] (CBC) with differential count
* Blood chemistry studies
:* [[Pancytopenia]] or a [[leukemic]] presentation with extensive [[leukocytosis]].<ref>{{Cite journal
* [[Cytogenetic analysis]]
| author = [[Ana Ferrer]], [[Itziar Salaverria]], [[Francesc Bosch]], [[Neus Villamor]], [[Maria Rozman]], [[Silvia Bea]], [[Eva Gine]], [[Armando Lopez-Guillermo]], [[Elias Campo]] & [[Emili Montserrat]]
| title = Leukemic involvement is a common feature in mantle cell lymphoma
| journal = [[Cancer]]
| volume = 109
| issue = 12
| pages = 2473–2480
| year = 2007
| month = June
| doi = 10.1002/cncr.22715
| pmid = 17477385
}}</ref>
* [[Comprehensive metabolic panel]]<ref>{{Cite journal
| author = [[Julie M. Vose]]
| title = Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
| journal = [[American journal of hematology]]
| volume = 92
| issue = 8
| pages = 806–813
| year = 2017
| month = August
| doi = 10.1002/ajh.24797
| pmid = 28699667
}}</ref>
* [[LDH]] levels<ref>{{Cite journal
| author = [[Julie M. Vose]]
| title = Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
| journal = [[American journal of hematology]]
| volume = 92
| issue = 8
| pages = 806–813
| year = 2017
| month = August
| doi = 10.1002/ajh.24797
| pmid = 28699667
}}</ref>: Normal range is 100–190 U/L
* [[Hepatitis B/Laboratory Tests|Hepatitis B]] testing if treatment with [[rituximab]] is planned<ref>{{Cite journal
| author = [[Arturo Ciccullo]], [[F. R. Ponziani]], [[E. Maiolo]], [[F. Pallavicini]] & [[M. Pompili]]
| title = Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report
| journal = [[Infection]]
| year = 2018
| month = October
| doi = 10.1007/s15010-018-1242-1
| pmid = 30368733
}}</ref>
* [[Uric acid]] levels: Normal range is 2.4-6.0 mg/dL in females and 3.4-7.0 mg/dL in males.
* [[Beta-2-microglobulin]]<ref>{{Cite journal
| author = [[Julie M. Vose]]
| title = Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management
| journal = [[American journal of hematology]]
| volume = 92
| issue = 8
| pages = 806–813
| year = 2017
| month = August
| doi = 10.1002/ajh.24797
| pmid = 28699667
}}</ref>: Normal range is 0-3 µg/mL.
* Pregnancy testing in woman of child-bearing age
* [[Flow cytometry]]
* [[Flow cytometry]]
* Immunohistochemistry
* [[Immunohistochemistry]]<ref>{{Cite journal
* [[Genetic testing]]
| author = [[Francesco Bertoni]], [[Emanuele Zucca]] & [[Finbarr E. Cotter]]
:* Heavy and light chain genes rearranged, t(11;14)(q13;q32) in virtually all cases
| title = Molecular basis of mantle cell lymphoma
:* Overexpression CYCLIN D [[mRNA]]
| journal = [[British journal of haematology]]
:* Mutation or deletions of ''ATM gene''
| volume = 124
* [[FISH]] (fluorescence in situ hybridization)
| issue = 2
* [[PCR]]  
| pages = 130–140
:*[[Polymerase chain reaction]] (PCR) and CER3 clonotypic primers are additional methods, but are less often used.
| year = 2004
* [[Immunophenotyping]]
| month = January
:*''BCL6-'', [[CD5]]+, [[CD10]]-, [[CD23]]- (or weakly positive), [[CD43]]+, FMC7+
| pmid = 14687022
 
}}</ref><ref>{{Cite journal
 
| author = [[Chan Yoon Cheah]], [[John F. Seymour]] & [[Michael L. Wang]]
| title = Mantle Cell Lymphoma
| journal = [[Journal of clinical oncology : official journal of the American Society of Clinical Oncology]]
| volume = 34
| issue = 11
| pages = 1256–1269
| year = 2016
| month = April
| doi = 10.1200/JCO.2015.63.5904
| pmid = 26755518
}}</ref>
:* [[CD19]], [[CD20]], [[CD22]], [[CD43]], [[CD79a]], [[CD5]], and [[FMC7]] typically are positive, whereas [[CD23]], [[CD10]], [[CD200]], and [[BCL6]] are usually negative
:* Overexpression of [[Cyclin D1]]
:* [[SOX11]] expression
* [[Genetic testing]]<ref>{{Cite journal
| author = [[Jordi Camps]], [[Itziar Salaverria]], [[Maria J. Garcia]], [[Esther Prat]], [[Silvia Bea]], [[Jessica C. Pole]], [[Lluis Hernandez]], [[Javier Del Rey]], [[Juan Cruz Cigudosa]], [[Marta Bernues]], [[Carlos Caldas]], [[Dolors Colomer]], [[Rosa Miro]] & [[Elias Campo]]
| title = Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines
| journal = [[Leukemia research]]
| volume = 30
| issue = 8
| pages = 923–934
| year = 2006
| month = August
| doi = 10.1016/j.leukres.2005.11.013
| pmid = 16448697
}}</ref>
:* [[Chromosomal translocation|Translocation]] t(11;14)(q13;q32) in virtually all cases
:* [[Mutation]] or deletions of ''[[ATM]] gene''
* [[FISH]] ([[fluorescence in situ hybridization]]):
** [[FISH]] can be used to detect the [[Chromosomal translocation|translocation]] t(11;14), which is found in most of [[MCL]] patients.<ref>{{Cite journal
| author = [[Tsieh Sun]], [[Mary Lowery Nordberg]], [[James D. Cotelingam]], [[Diana M. Veillon]] & [[John Ryder]]
| title = Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma
| journal = [[American journal of hematology]]
| volume = 74
| issue = 1
| pages = 78–84
| year = 2003
| month = September
| doi = 10.1002/ajh.10356
| pmid = 12949897
}}</ref>
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 20:42, 7 January 2019

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma laboratory findings

on Mantle cell lymphoma laboratory findings

Mantle cell lymphoma laboratory findings in the news

Blogs on Mantle cell lymphoma laboratory findings

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2] Sowminya Arikapudi, M.B,B.S. [3]

Overview

Laboratory tests for mantle cell lymphoma include complete blood count (CBC), comprehensive metabolic panel, LDH levels, Hepatitis B testing if treatment with rituximab is planned, uric acid levels, beta-2-microglobulin, pregnancy testing in woman of child-bearing age, flow cytometry, immunohistochemistry, genetic testing and FISH.

Laboratory tests

Laboratory tests for mantle cell lymphoma include:[1]

References

  1. ↑ https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
  2. ↑ Ana Ferrer, Itziar Salaverria, Francesc Bosch, Neus Villamor, Maria Rozman, Silvia Bea, Eva Gine, Armando Lopez-Guillermo, Elias Campo & Emili Montserrat (2007). "Leukemic involvement is a common feature in mantle cell lymphoma". Cancer. 109 (12): 2473–2480. doi:10.1002/cncr.22715. PMID 17477385. Unknown parameter |month= ignored (help)
  3. ↑ Julie M. Vose (2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". American journal of hematology. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667. Unknown parameter |month= ignored (help)
  4. ↑ Julie M. Vose (2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". American journal of hematology. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667. Unknown parameter |month= ignored (help)
  5. ↑ Arturo Ciccullo, F. R. Ponziani, E. Maiolo, F. Pallavicini & M. Pompili (2018). "Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report". Infection. doi:10.1007/s15010-018-1242-1. PMID 30368733. Unknown parameter |month= ignored (help)
  6. ↑ Julie M. Vose (2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". American journal of hematology. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667. Unknown parameter |month= ignored (help)
  7. ↑ Francesco Bertoni, Emanuele Zucca & Finbarr E. Cotter (2004). "Molecular basis of mantle cell lymphoma". British journal of haematology. 124 (2): 130–140. PMID 14687022. Unknown parameter |month= ignored (help)
  8. ↑ Chan Yoon Cheah, John F. Seymour & Michael L. Wang (2016). "Mantle Cell Lymphoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34 (11): 1256–1269. doi:10.1200/JCO.2015.63.5904. PMID 26755518. Unknown parameter |month= ignored (help)
  9. ↑ Jordi Camps, Itziar Salaverria, Maria J. Garcia, Esther Prat, Silvia Bea, Jessica C. Pole, Lluis Hernandez, Javier Del Rey, Juan Cruz Cigudosa, Marta Bernues, Carlos Caldas, Dolors Colomer, Rosa Miro & Elias Campo (2006). "Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines". Leukemia research. 30 (8): 923–934. doi:10.1016/j.leukres.2005.11.013. PMID 16448697. Unknown parameter |month= ignored (help)
  10. ↑ Tsieh Sun, Mary Lowery Nordberg, James D. Cotelingam, Diana M. Veillon & John Ryder (2003). "Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma". American journal of hematology. 74 (1): 78–84. doi:10.1002/ajh.10356. PMID 12949897. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mantle_cell_lymphoma_laboratory_findings&oldid=1515331"